BIA biotech manifesto 2019

In this blog, Matej Metkovic, CEO and Founder of Wasteless Bio, explores the valuable unused equipment sitting in labs that quietly erodes in worth.

Proceeds will enable generation of full clinical data from ongoing Phase 1 study of TROCEPT-01 (ATTR-01), its lead programme in advanced solid tumours, and progression of TROCEPT-02 (ATTR-02) into the clinic.

In this blog, Blood Cancer UK reflects on a year of partnership with BIA — from raising vital funds and forging new connections in life sciences, to amplifying the voice of people affected by blood cancer across the UK.

Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.